E6 associates with p53 and targets it for rapid degradation mediated by the ubiquitin ligase E6-associated protein (E6-AP), which does not recognize the free tumor suppressor. Inactivation of the ...
Here we describe the generation and characterization of green fluorescent protein (GFP)-based substrates that allow rapid quantification of ubiquitin–proteasome-dependent proteolysis in living ...
My group focuses on understanding cell signaling pathways primarily linked with the ubiquitin and autophagy systems and frequently altered in diseases ... Central to our research efforts, we employ ...
which tag single disease proteins with the marker protein ubiquitin, leading to their degradation via 26S proteasomes. This can be effective, particularly in diseases driven by a single errant ...
My research lab at William & Mary studies the function of protein modifiers and degraders in yeast and mammalian model systems. My research specialties encompass the role that SUMO and ubiquitin play ...
The tag is a small protein called ubiquitin, which effectively gets fired at the disease-causing protein like a bullet. In ...
However, the relationship between the enzymes and their corresponding substrates has not yet been well established, and the development of technology that comprehensively analyzes the ubiquitin system ...
Vishnudas, Ph.D., Chief Technology Officer and R&D Site Head, will present a session titled, "A Novel & Differentiated Approach to Targeted Protein Degradation – Leveraging the Ubiquitin ...
Arcus Biosciences Inc. has synthesized new E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.
Scientists at Inventisbio Co. Ltd. and Inventisbio LLC have divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.